Archive for cellular and molecular medicine
Building better antibodies, curbing autoimmunity: New insights on B cells
When we’re vaccinated or exposed to an infection, our B cells spring into action, churning out antibodies that are increasingly potent, specific, and protective. This happens through an iterative process known as affinity maturation. Two labs at Boston Children’s Hospital have come up with different ways to enhance affinity maturation and help B cells make ... Read More about Building better antibodies, curbing autoimmunity: New insights on B cells
Exposing a tumor’s antigens to enhance immunotherapy
Successful immunotherapy for cancer involves activating a person’s own T cells to attack the tumor. But some tumors have a trick: They hide themselves from the immune system by preventing their antigens from being displayed, a necessary step in activating T cells. In new work published in Science, researchers in the Program in Cellular and ... Read More about Exposing a tumor’s antigens to enhance immunotherapy
Could the right dietary fat help boost platelet counts?
Aside from transfusions, there currently is no way to boost people’s platelet counts, leaving them at risk for uncontrolled bleeding. Could something as simple as a dietary change raise platelet counts in people with low levels, such as cancer patients receiving chemotherapy? New science out of the lab suggests that the answer might be yes. ... Read More about Could the right dietary fat help boost platelet counts?
Tackling an aggressive, treatment-resistant lymphoma where it lives
Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30 percent of cases. When tumors are driven by the oncogene ALK — which is the case for the majority of children — kinase inhibitor drugs like crizotinib are very effective ... Read More about Tackling an aggressive, treatment-resistant lymphoma where it lives
One-time treatment could block a deadly form of graft-versus-host disease
Even when a bone marrow transplant cures leukemia or lymphoma, patients can still pass away from graft-versus-host disease (GVHD), in which T cells in the donor graft attack the recipient’s own tissues. Leslie Kean, MD, PhD, director of stem cell transplant at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, has long sought to prevent this ... Read More about One-time treatment could block a deadly form of graft-versus-host disease
Immune biomarkers predicted COVID-19 severity and could help in future pandemics
Why did some people fall critically ill from COVID-19 and others not? In May 2020, as COVID-19 swept the world, Boston Children’s Hospital helped launch a national, NIAID-funded study called IMPACC (IMmunoPhenotyping Assessment in a COVID-19 Cohort). Taking a “systems immunology” approach, the goal was to document the virus’s impact on the immune system in ... Read More about Immune biomarkers predicted COVID-19 severity and could help in future pandemics
A new cancer mechanism: Failed cellular housekeeping
Cancer can stem from mutations in many different genes. New research from Boston Children’s Hospital and Dana-Farber Cancer Institute pinpoints a gene that, when mutated, causes cancer through a mechanism not before seen: Inability of cells to dispose of their trash, namely defective strands of RNA. This mechanism appears to cut across many different malignancies, ... Read More about A new cancer mechanism: Failed cellular housekeeping
An unexpected journey reveals a potent way to attack tumors
Research on the effects of prenatal exposure to the Zika virus has yielded an unexpected dividend: a potentially promising way to trigger natural killer (NK) cells to fight cancer. NK cells are first-responder immune cells. When enough of their activating receptors are triggered, they mobilize to kill infected, stressed, or cancerous cells at an early ... Read More about An unexpected journey reveals a potent way to attack tumors
Going out of the box to tackle pancreatic cancer
Pancreatic cancers are deadly and hard to treat, in part because they are so often detected at an advanced stage; overall five-year survival rates are about 11 percent. Two separate labs at Boston Children’s Hospital took out-of-the-box approaches to this difficult cancer, and both uncovered some very promising leads. Wiping out pancreatic tumors’ immune defense ... Read More about Going out of the box to tackle pancreatic cancer
Tim Springer: Scientist, entrepreneur, and mentor
As an undergraduate in 1966, immunologist, biochemist, and biophysicist Timothy A. Springer, PhD, looked askance at science. The Vietnam War was going on, and he saw science as a means of making Agent Orange and napalm. Questioning his own Ivy League education, he left Yale to spend a year as a VISTA volunteer on a ... Read More about Tim Springer: Scientist, entrepreneur, and mentor